Formulation D

DRUG5 trials

Sponsors

GlaxoSmithKline, Janssen Sciences Ireland UC, Lyndra Inc., Inventprise Inc.

Conditions

Gastric RetentionHealthyMultiple SclerosisPneumococcal Disease, InvasiveSleep Initiation and Maintenance Disorders

Early Phase 1

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

CompletedNCT03718390

Lyndra Inc.Gastric Retention, Healthy

Start: 2018-06-25End: 2018-11-02Updated: 2019-02-26

Phase 1

Bioequivalence and Food Effect Study in Healthy Volunteers

CompletedNCT00495274

GlaxoSmithKlineSleep Initiation and Maintenance Disorders

Start: 2007-07-02End: 2007-09-26Updated: 2017-08-07

Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

CompletedNCT00548769

GlaxoSmithKlineMultiple Sclerosis

Start: 2007-04-21End: 2007-11-26Updated: 2017-08-01

Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

CompletedNCT02426632

Janssen Sciences Ireland UCHealthy

Start: 2015-03-04End: 2015-04-24Updated: 2018-05-15

Phase 2

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants

Active, not recruitingNCT06790290

Inventprise Inc.Pneumococcal Disease, Invasive

Start: 2025-01-27End: 2026-12-31Updated: 2025-09-02